SynKIR-110: Autologous T cells Transduced with Mesothelin KIR-CAR
SynKIR-310: Autologous T Cells transduced with CD19 KIR-CAR
Study summary
The primary purpose of this study is to monitor potential long-term risks associated with the administration of SynKIR CAR T cell products.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
Participants are eligible to be included in the study only if all of the following criteria apply:
1. All adult participants who have received any amount of SynKIR CAR T cell product in a study sponsored by Verismo Therapeutics.
2. Participant is willing and able to comply with the study requirements.
Exclusion Criteria:
There are no specific exclusion criteria.
Primary outcome measure(s)
To monitor the long-term safety of participants that have been infused with a SynKIR CAR T cell product — Up to 15 years from SynKIR CAR T cell product administration Frequency and severity of delayed AEs considered related to SynKIR CAR T cell product
To monitor the long-term safety of participants that have been infused with a SynKIR CAR cell product — Up to 15 years from SynKIR CAR T cell product administration Presence of RCL VSV-G DNA
Trial sites (7)
Facility
City
Region
Status
Colorado Blood Cancer Institute, part of Sarah Cannon Research Institute
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.